U.S. FDA approves AstraZeneca-Merck’s Lynparza to treat early-stage breast cancer, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

AstraZeneca said on Friday the drug, Lynparza, was approved for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery., AstraZeneca said on Friday the drug, Lynparza, was approved for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery., , Read More